Monday, August 20, 2018
Company News: Page (1) of 1 - 04/03/18 Email this story to a friend. email article Print this page (Article printing at page facebook
genedrive to premier its GenedriveŽ Hepatitis C test in Asia Pacific

(April 03, 2018)

3 April 2018

genedrive plc ("genedrive" or the "Company")


GenedriveŽ HCV ID Kit to be presented at MEDLAB Asia Pacific Exhibition & Congress

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces it will premiere its GenedriveŽ HCV ID Kit in the Asia Pacific region at the MEDLAB Asia Pacific Exhibition & Congress in Singapore on 2-4 April 2018.

GenedriveŽ HCV ID Kit is a qualitative HCV assay, providing results within 90 minutes and is designed for use in a decentralised testing environment. It is performed on the company's portable molecular diagnostics platform, GenedriveŽ, and was created to support the roll-out of direct-acting antivirals in low and middle income countries.

genedrive recently announced first commercial sales of instruments and assays to Sysmex Europe GmbH to cover Europe, Middle East and Africa and Sysmex Asia Pacific Pte Ltd for the Asia Pacific region, excluding India. In addition, the GenedriveŽ HCV ID Kit's first external validation study was successfully conducted in South Africa with results announced in early January 2018 showing 100% specificity and sensitivity in independent use, confirming that our good clinical validation performance can be translated into real-world settings.

MEDLAB is a significant and highly attended event in the Asia Pacific region for leading companies to showcase their technologies and innovations in the field of laboratory diagnostics. With over 4,000 delegates from around the world, the congress features products in many areas including point of need and infectious diseases.

The GenedriveŽ HCV-ID Kit will be presented and demonstrated together with Sysmex Asia Pacific at booth M19 at the Suntec Singapore Convention & Exhibition Centre.

-  Ends  -

For further details please contact:
genedrive plc
David Budd: CEO                                                                                                              +44 (0)161 989 0245
Matthew Fowler: CFO

Peel Hunt LLP
James Steel                                                                                                                      +44 (0)207 418 8900
Oliver Jackson

Consilium Strategic Communications
Chris Gardner                                                                                                                    +44 (0)203 709 5700
Matthew Neal
Laura Thornton
[email protected] 

Notes to Editors

About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The GenedriveŽ HCV ID Kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the GenedriveŽ platform in the EMEA  and SE Asia (ex India), and with ARKRAY Healthcare pvt Ltd for the distribution of the GenedriveŽ HCV ID Kit and GenedriveŽ platform in India.

Further details can be found at: and

About Hepatitis C
Hepatitis C (HCV) is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150-200 million people, or approximately 3% of the world's population, are living with chronic HCV, and more than 350,000 people die yearly from HCV related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate HCV.

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • Global Hemodialysis and Peritoneal Dialysis Market to Witness a CAGR of 5.9% during 2018-2024
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain LongevityŽ Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023
  • Disposable Negative Pressure Wound Therapy Devices Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2027)

  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  • Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
  • Agenus Receives Second Milestone Payment from Merck

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines